The U.K.’s Medicines and Healthcare Products Regulatory Agency and the China Food and Drug Administration signed a memorandum of understanding on drug regulation, focused on sharing information from accelerated access reviews and developing effective ways of regulating online medicine trading.

The new agreement expands upon a 2014 MoU on sharing safety information.

China is “a world leader in the market for raw materials for the pharmaceutical industry and closer collaboration with MHRA will support the promotion of innovation, good practice, and protect U.K. patients,” said MHRA Chief Executive Ian Hudson.